<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152643</url>
  </required_header>
  <id_info>
    <org_study_id>CLBR-CBSET</org_study_id>
    <nct_id>NCT03152643</nct_id>
  </id_info>
  <brief_title>Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer</brief_title>
  <acronym>CLBR-CBSET</acronym>
  <official_title>Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer:A Multicenter, Prospective, Randomized, Blinded Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The success of assisted reproductive technology (ART) is to achieve healthy live births with
      high utilization rate of embryos and low rate of adverse effects. Previous studies showed
      that live birth rates slightly increased after single blastocyst-stage embryo transfer
      compared with single cleavage-stage embryo transfer, however cumulative pregnancy rates
      between the two groups decreased significantly. So far there is lack of data on cumulative
      live birth rates. The aim of the present study is to compare cumulative live birth rates
      after cleavage-stage and blastocyst-stage embryo transfer in IVF/ICSI treatment cycles.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative survival rate</measure>
    <time_frame>12-14months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>abortion rate</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo freezing rate</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal outcome-gestational age</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal birth weight</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal sex ratio</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal complications</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>monozygotic twin rates</measure>
    <time_frame>12-14months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Cumulative Live Birth Rates</condition>
  <condition>Embryo Transfer</condition>
  <arm_group>
    <arm_group_label>blastocyst-stage Day 5 embryo transfer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cleavage-stage Day 3 embryo transfer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blastocyst-stage embryo transfer</intervention_name>
    <description>To transfer embryos on blastocyst-stage Day 5</description>
    <arm_group_label>blastocyst-stage Day 5 embryo transfer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cleavage-stage embryo transfer</intervention_name>
    <description>To transfer embryos on cleavage-stage Day 3</description>
    <arm_group_label>cleavage-stage Day 3 embryo transfer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Routine ART treatment;

          2. Number of high quality embryos â‰¥ 4 on Day 4;

          3. Written informed consent provided. -

        Exclusion Criteria:

          1. Patients aged &gt;40 years;

          2. Untreated hydrosalpinx;

          3. Uterine abnormality (confirmed by three-dimensional ultrasonography or hysteroscopy);

          4. Use of IVM;

          5. Use of PGD/PGS;

          6. Patients with contraindications for ART. -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Center of Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiang Ma, MD</last_name>
    <phone>+8613770681878</phone>
    <email>sxmaxiang@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Wang, MD</last_name>
    <phone>+86186651618366</phone>
    <email>wjbonnie@163.com</email>
  </overall_contact_backup>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

